T. Macarulla Mercadé

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Dejan Juric, Johann S. de Bono, Patricia LoRusso et al. · Clinical Cancer Research · 2017 · 89 citations · Full text

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

Ghassan K. Abou‐Alfa, T. Macarulla Mercadé, Milind Javle et al. · Annals of Oncology · 2019 · 88 citations

Tumor Biology, Isocitrate Dehydrogenase 1, Oncology +10

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

Ma A. Gómez-España, Ana Fernández Montés, Rocio García‐Carbonero et al. · Clinical & Translational Oncology · 2021 · 46 citations · Full text